Loading
When the tumour shows little PD-L1, immunotherapy alone is weak, but adding chemotherapy makes it work for most patients.
This combination gives a PD-1 checkpoint inhibitor together with cytotoxic chemotherapy in non-small-cell lung cancer whose PD-L1 tumour proportion score is low. Chemotherapy releases tumour antigen and depletes suppressive cells, priming an immune response that PD-1 blockade then sustains, and the benefit does not depend on the PD-L1 level. KEYNOTE-189 in non-squamous and KEYNOTE-407 in squamous disease showed an overall survival benefit across PD-L1 strata, including tumours with essentially no PD-L1 expression. POSEIDON adds tremelimumab to durvalumab and chemotherapy for PD-L1-negative and STK11- or KEAP1-mutant disease. Pembrolizumab with chemotherapy is now the standard control arm against which every new first-line lung regimen is measured.
Shares KEYNOTE-024 & KEYNOTE-189, Tumour proportion score (TPS), PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab.
Shares Tremelimumab, Durvalumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Tremelimumab, Durvalumab, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.